The Experts below are selected from a list of 216 Experts worldwide ranked by ideXlab platform

Carl Grumet - One of the best experts on this subject based on the ideXlab platform.

  • typing of serum soluble HLA B27 Antigen by elisa
    Tissue Antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

  • Typing of serum‐soluble HLA‐B27 Antigen by ELISA
    Tissue antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

Philippe Pouletty - One of the best experts on this subject based on the ideXlab platform.

  • typing of serum soluble HLA B27 Antigen by elisa
    Tissue Antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

  • Typing of serum‐soluble HLA‐B27 Antigen by ELISA
    Tissue antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

Fabrice Michel - One of the best experts on this subject based on the ideXlab platform.

  • Spondyloarthropathy and retroperitoneal fibrosis: a case report.
    Joint Bone Spine, 2002
    Co-Authors: Daniel Wendling, Eric Toussirot, Fabrice Michel
    Abstract:

    Abstract Retroperitoneal fibrosis is an uncommon inflammatory condition in which the retroperitoneal tissue is transformed into a tight sheet of fibrous tissue. It can occur in association with various diseases, including rheumatic conditions. We report a new case in a 66-year-old man with spondyloarthropathy. Nine similar cases have been reported. Axial manifestations predominated, and half the patients carried the HLA-B27 Antigen. The relation between retroperitoneal fibrosis and spondyloarthropathy remains controversial.

Bob Shimizu - One of the best experts on this subject based on the ideXlab platform.

  • typing of serum soluble HLA B27 Antigen by elisa
    Tissue Antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

  • Typing of serum‐soluble HLA‐B27 Antigen by ELISA
    Tissue antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

Elizabeth Atwood - One of the best experts on this subject based on the ideXlab platform.

  • typing of serum soluble HLA B27 Antigen by elisa
    Tissue Antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.

  • Typing of serum‐soluble HLA‐B27 Antigen by ELISA
    Tissue antigens, 1993
    Co-Authors: Philippe Pouletty, Chin Chang, Jorge Kalil, Elizabeth Atwood, Soldane Ferrone, Bob Shimizu, William Howson, Reza Mazaheri, Bart Del Villano, Carl Grumet
    Abstract:

    An ELISA using serum as soluble HLA Antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 Antigens; the other assay utilized a mAb reactive with HLA-B7 Antigens but not with HLA-B27 Antigens. After incubation with serum samples, bound HLA Antigen was detected using an anti-beta 2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 Antigen reactivity and the amount of total HLA class I Antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA Antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.